Essential character and customs valuation rules govern vaccine classification and cost-based valuation, favouring the assessee.

Recombinant hepatitis-B surface antigen bulk and the corresponding vaccine products were treated as vaccines and similar products under Heading 30.02 because their essential character lay in inducing antibodies and conferring immunity; Heading 35.04 applied only to protein substances not elsewhere specified, so classification favoured the assessee. For valuation, Rule 8 of the Customs Valuation Rules could not be used to adopt the domestic selling price of comparable Indian goods, because the scheme required acceptance of the manufacturing cost plus profit method under Rule 7A. The impugned orders were therefore set aside, and the demand and penalties did not survive.

---

---

Issues: (i) Whether recombinant hepatitis-B surface antigen bulk and the corresponding vaccine products were classifiable under Heading 30.02 as vaccines and similar products or under Heading 35.04 as other protein substances; (ii) whether the assessable value of the vaccine manufactured by Serum Institute could be determined under Rule 8 of the Customs Valuation Rules, 1988 on the basis of the selling price of comparable Indian goods, or had to be accepted on the manufacturing cost plus profit method under Rule 7A.

Issue (i): Whether recombinant hepatitis-B surface antigen bulk and the corresponding vaccine products were classifiable under Heading 30.02 as vaccines and similar products or under Heading 35.04 as other protein substances.

Analysis: The product, though produced in bulk and capable of being formulated with adjuvant, was found to possess the essential character of a vaccine because its function was to induce antibodies and confer immunity. Heading 30.02 covers vaccines and similar products even in bulk form, while Heading 35.04 applies only to protein substances not elsewhere specified or included. Applying the classification principles and the rule of essential character, the product was treated as a vaccine rather than as a mere purified protein.

Conclusion: The products were classifiable under Heading 30.02, not under Heading 35.04, and the classification was in favour of the assessee.

Issue (ii): Whether the assessable value of the vaccine manufactured by Serum Institute could be determined under Rule 8 of the Customs Valuation Rules, 1988 on the basis of the selling price of comparable Indian goods, or had to be accepted on the manufacturing cost plus profit method under Rule 7A.

Analysis: Rule 8 does not permit valuation on the basis of the selling price in India of goods produced in India. The valuation adopted by the department was therefore inconsistent with the scheme of the Customs Valuation Rules. The assessee's method based on manufacturing cost plus profit under Section 14 of the Customs Act, 1962 read with Rule 7A was accepted as the correct method.

Conclusion: The transaction value of Genevac-B was required to be accepted, and this issue was decided in favour of the assessee.

Final Conclusion: The impugned orders were set aside, the appeals were allowed, and the demand and penalties could not survive.

Ratio Decidendi: For tariff classification, a product must be placed in the heading that correctly reflects its essential character and specific use, and for customs valuation Rule 8 cannot be used to determine value on the basis of the domestic selling price of goods manufactured in India when the applicable rule requires acceptance of cost-based valuation.

---